Your search returned 6 results.

Results
	1.	Unravelling mechanisms of cisplatin sensitivity and resistance in testicular cancer. [electronic resource] by Koster, R van Vugt, M A T M Timmer-Bosscha, H Gietema, J A de Jong, S Producer: 20140312 In: Expert reviews in molecular medicine vol. 15 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	2.	ATR inhibition preferentially targets homologous recombination-deficient tumor cells. [electronic resource] by Krajewska, M Fehrmann, R S N Schoonen, P M Labib, S de Vries, E G E Franke, L van Vugt, M A T M Producer: 20150921 In: Oncogene vol. 34 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	3.	Forced activation of Cdk1 via wee1 inhibition impairs homologous recombination. [electronic resource] by Krajewska, M Heijink, A M Bisselink, Y J W M Seinstra, R I Silljé, H H W de Vries, E G E van Vugt, M A T M Producer: 20130814 In: Oncogene vol. 32 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	4.	Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer. [electronic resource] by Alkema, N G Tomar, T van der Zee, A G J Everts, M Meersma, G J Hollema, H de Jong, S van Vugt, M A T M Wisman, G B A Producer: 20140716 In: Gynecologic oncology vol. 133 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	5.	Rectal and colon cancer: Not just a different anatomic site. [electronic resource] by Tamas, K Walenkamp, A M E de Vries, E G E van Vugt, M A T M Beets-Tan, R G van Etten, B de Groot, D J A Hospers, G A P Producer: 20151106 In: Cancer treatment reviews vol. 41 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	6.	A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: the DoCaCel study. [electronic resource] by Reyners, A K L de Munck, L Erdkamp, F L G Smit, W M Hoekman, K Lalisang, R I de Graaf, H Wymenga, A N M Polee, M Hollema, H van Vugt, M A T M Schaapveld, M Willemse, P H B Producer: 20130429 In: Annals of oncology : official journal of the European Society for Medical Oncology vol. 23 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)